Your session is about to expire
← Back to Search
This trial will test whether the anti-diabetic medication liraglutide can reduce the risk of cardiovascular disease by reducing inflammation in the Epicardial Adipose Tissue (EAT).
- Coronary Artery Disease
- Type 2 Diabetes
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Adults with type 2 diabetes who need liraglutide, along with diet and exercise, to manage their blood sugar levels, but haven't started it as their first treatment.You or your family have a history of a specific type of thyroid cancer or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2.You had a serious allergic reaction to liraglutide before.You have other health conditions that make it unsafe for you to take liraglutide, as listed in the most recent safety information.You have a history of severe diabetes complications, certain diseases, or drug abuse.You have ongoing inflammation-related conditions like severe infections, arthritis, skin problems, asthma, or bowel inflammation.You have been taking strong medicines called corticosteroids in the last 3 months.You have type 2 diabetes as diagnosed by the American Diabetes Association criteria.Your hemoglobin A1c level is less than or equal to 9%.You have stable coronary artery disease and need coronary artery bypass graft surgery as part of your regular medical care. This condition does not prevent you from using liraglutide. Your stable condition ensures that taking liraglutide will not increase your health risks.People with stable heart disease needing coronary artery bypass surgery can join the study, as their condition won't make it risky to use liraglutide.Adults with type 2 diabetes who need to take liraglutide, along with diet and exercise, to control their blood sugar.You have a higher than normal body mass index (BMI) or waist circumference.You have stable coronary artery disease and may need coronary artery bypass grafting (CABG) as part of your regular medical care. This condition won't stop you from using liraglutide, and your heart condition won't be at higher risk by taking liraglutide.Adults with type 2 diabetes who need to take liraglutide, along with diet and exercise, to better control their blood sugar.You have type 1 diabetes according to the American Diabetes Association criteria.You are currently taking certain types of diabetes medications, including GLP-1A, DPP4, SGLT2 inhibitors, TZDs, pramlintide, or fixed prandial insulin.You have unstable coronary artery disease, which means you have new or worsening chest pain.
- Group 1: L-group
- Group 2: D-group
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What indications might necessitate the use of L-group medications?
"L-group can be employed to assist with cardio risk minimisation, physical fitness and reducing the impact of single drug therapy."
Is this research study still recruiting participants?
"As detailed by clinicaltrials.gov, the enrollment for this medical trial is now open to participants. The study was first made available on September 1st 2018 and underwent its most recent edit in November 4th 2022."
Could you provide a tally of participants in this research study?
"Correct. Recent information from clinicaltrials.gov confirms that this research is still seeking participants, having first been posted on September 1st 2018 and revised as recently as November 4th 2022. 40 persons need to be recruited at a single site."
Are there any potential health risks associated with using L-group medications?
"There is a considerable amount of data that attests to the safety of L-group, resulting in it receiving a score of 3. This Phase 4 trial confirms its approval as an effective treatment option."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends